Literature DB >> 2843982

In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

M Rylander1, H O Hallander.   

Abstract

The in vitro activities of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against clinical isolates of Mycoplasma pneumoniae (n = 3), Mycoplasma hominis (n = 64) and Ureaplasma urealyticum (n = 33), were compared using an agar dilution method. M. pneumoniae seemed equally susceptible to the two tetracyclines, while the minimum inhibitory concentrations (MICs) of doxycycline were one or two dilution steps lower than the MICs of tetracycline for most strains of M. hominis and U. urealyticum. Ten of the 64 M. hominis strains required greater than or equal to 32 mg/l of tetracycline and 4 to 32 mg/l of doxycycline for inhibition. The MICs of CP 62993 were lower than those of erythromycin for all species tested although as much as 2 to 4 mg/l were required for inhibition of M. hominis. There is microbiological evidence that doxycycline as well as tetracycline might be effective against mycoplasmas and ureaplasmas. For erythromycin this is only true for M. pneumoniae and U. urealyticum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843982

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  12 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Gynaecological tissue levels of azithromycin.

Authors:  K Krohn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 4.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

5.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Septic osteomyelitis and polyarthritis with ureaplasma in hypogammaglobulinemia.

Authors:  C Jorup-Rönström; T Ahl; L Hammarström; C I Smith; M Rylander; H Hallander
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

Review 7.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

8.  Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 10.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.